US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Aurinia Pharmaceuticals Inc.

< Previous 1 2 3 4 Next >
News headline image
Aurinia Announces PTAB Has Terminated Inter Partes Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports First Quarter 2022 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
< Previous 1 2 3 4 Next >